Want to see ELTX full AI Analyst Report?
Top Page
Elicio Therapeutics
(NASDAQ:ELTX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-50.17% Downside)
Action:Reiterated
Date:09/11/26
ELTX scores low primarily due to weak financial performance (no revenue, large recurring losses, and persistent ~$37M+ annualized cash burn) and a clearly bearish technical trend (price below all key moving averages with negative MACD and very weak RSI/Stoch). Corporate updates provide some offset via financing and select clinical-response observations, but the missed Phase 2 primary endpoint and ongoing funding dependence keep overall risk elevated, while valuation metrics offer limited support given negative earnings and no dividend data.
Positive Factors
Targeted immunotherapy platform
Elicio’s AMP platform provides a defined technological approach to enhancing tumor-specific T cell responses by directing immune agents toward lymph nodes. If clinical development validates this mechanism, the platform could support multiple cancer programs rather than relying on a single asset.
Negative Factors
No commercial revenue
Elicio has not yet demonstrated commercial revenue generation across several reporting periods, leaving the business dependent on clinical success before it can build an operating revenue base. This increases exposure to development delays and makes future funding needs more significant.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted immunotherapy platform
Elicio’s AMP platform provides a defined technological approach to enhancing tumor-specific T cell responses by directing immune agents toward lymph nodes. If clinical development validates this mechanism, the platform could support multiple cancer programs rather than relying on a single asset.
Read all positive factors
Elicio Therapeutics (ELTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$49.67M
Dividend YieldN/A
Average Volume (3M)334.74K
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue GrowthN/A
EPS Growth49.43%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.13
Shares Outstanding26,281,881
10 Day Avg. Volume260,605
30 Day Avg. Volume334,742
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-228.08
Enterprise Value/Ebitda-1.64
Forecast
1Y Price Target
$15.50Price Target Upside414.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.89
Revenue Forecast (FY)N/A
Elicio Therapeutics Business Overview & Revenue Model
Company Description
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an A...
Elicio Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.31M |
| Gross Profit | -289.00K | -1.13M | -1.18M | -1.17M | -1.06M | 27.08M |
| EBITDA | -40.24M | -37.31M | -50.27M | -32.97M | -23.55M | -52.47M |
| Net Income | -37.84M | -39.57M | -51.90M | -35.20M | -28.21M | -26.40M |
Balance Sheet | ||||||
| Total Assets | 31.33M | 25.86M | 28.18M | 27.15M | 22.66M | 96.51M |
| Cash, Cash Equivalents and Short-Term Investments | 23.48M | 18.56M | 17.62M | 12.89M | 7.80M | 88.76M |
| Total Debt | 14.15M | 14.51M | 26.04M | 6.92M | 7.48M | 4.66M |
| Total Liabilities | 23.39M | 24.23M | 39.49M | 15.77M | 13.75M | 15.01M |
| Stockholders Equity | 7.94M | 1.64M | -11.31M | 11.37M | 8.91M | 81.51M |
Cash Flow | ||||||
| Free Cash Flow | -37.71M | -36.97M | -37.16M | -32.76M | -22.83M | -24.46M |
| Operating Cash Flow | -37.69M | -36.95M | -37.07M | -32.69M | -22.18M | -23.94M |
| Investing Cash Flow | -16.00K | -16.00K | -84.00K | -32.00K | -654.00K | -525.36K |
| Financing Cash Flow | 38.97M | 36.70M | 42.32M | 38.61M | 21.20M | 19.39M |
Elicio Therapeutics Technical Analysis
Negative
3.01
Price Trends
2.46
Negative
4.50
Negative
7.25
Negative
Market Momentum
-0.18
Negative
35.83
Neutral
45.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTX, the sentiment is Negative. The current price of 3.01 is above the 20-day moving average (MA) of 1.88, above the 50-day MA of 2.46, and below the 200-day MA of 7.25, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 35.83 is Neutral, neither overbought nor oversold. The STOCH value of 45.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELTX.
Elicio Therapeutics Risk Analysis
Elicio Therapeutics disclosed 93 risk factors in its most recent earnings report. Elicio Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elicio Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $201.77M | 5.67 | 42.57% | ― | 234.18% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $95.24M | -1.11 | -288.36% | ― | ― | 21.42% | |
42 Neutral | $49.67M | -0.89 | -1266.43% | ― | ― | 49.43% | |
42 Neutral | $26.94M | -1.14 | -60.32% | ― | ― | 71.26% |
* Healthcare Sector Average
ELTX
Elicio Therapeutics
1.89
-8.76
-82.25%
CGEN
Compugen
2.13
-0.11
-4.91%
MCRB
Seres Therapeutics
2.71
-16.52
-85.91%
MIST
Milestone Pharmaceuticals
0.77
-1.23
-61.56%
ACTU
Actuate Therapeutics, Inc.
0.61
-7.48
-92.46%
Elicio Therapeutics Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
Elicio Therapeutics Sets Key 2026 Shareholder Proposal Deadlines
Neutral
Sep 14, 2026
Elicio Therapeutics, Inc. has scheduled its 2026 annual meeting of stockholders for November 12, 2026, marking a significant change from the prior year’s meeting date and triggering revised timelines for shareholder participation. Additional...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.